Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 2:15:983-1003.
doi: 10.2147/JAA.S374346. eCollection 2022.

Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology

Baharudin Abdullah  1 , Amir Hamzah Abdul Latiff  2 , Anura Michelle Manuel  3 , Faizah Mohamed Jamli  4 , Harvinder Singh Dalip Singh  5 , Intan Hakimah Ismail  6 , Jeevanan Jahendran  2 , Jeyasakthy Saniasiaya  7 , Kent Chee Keen Woo  8 , Phaik Choo Khoo  9 , Kuljit Singh  3 , Nurashikin Mohammad  10 , Sakinah Mohamad  1 , Salina Husain  11 , Ralph Mösges  12   13
Affiliations

Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology

Baharudin Abdullah et al. J Asthma Allergy. .

Abstract

The goal of allergic rhinitis (AR) management is to achieve satisfactory symptom control to ensure good quality of life. Most patients with AR are currently treated with pharmacotherapy. However, knowledge gaps on the use of pharmacotherapy still exist among physicians, particularly in the primary care setting, despite the availability of guideline recommendations. Furthermore, it is common for physicians in the secondary care setting to express uncertainty regarding the use of new combination therapies like intranasal corticosteroid plus antihistamine combinations. Inadequate treatment leads to significant reduction of quality of life that affects daily activities at home, work, and school. With these concerns in mind, a practical consensus statement was developed to complement existing guidelines on the rational use of pharmacotherapy in both the primary and secondary care settings.

Keywords: Malaysia; allergic rhinitis; consensus; pharmacotherapy; primary care; secondary care.

PubMed Disclaimer

Conflict of interest statement

Jeevanan Jahendran reports personal fees from Inova Pharmaceuticals (S’pore) Pte. Ltd. (M’sia Branch), Viatris, Menarini Singapore Pte Ltd, Reckitt Benckiser (Malaysia) Sdn. Bhd., and (M) Sdn Bhd, outside the submitted work. Ralph Mösges reports personal fees from Menarini Asian Pacific, during the conduct of the study, and received personal fees from ALK, grants from ASIT biotech, personal fees from Allergopharma, Allergy Therapeutics, grants and personal fees from Bencard, grants from Leti, grants, personal fees and non-financial support from Lofarma, non-financial support from Roxall, grants and personal fees from Stallergenes, grants from Optima, personal fees from Friulchem, personal fees from Hexal, Servier, Klosterfrau, non-financial support from Atmos, personal fees from Bayer, non-financial support from Bionorica, personal fees from FAES, GSK, MSD, Johnson & Johnson, Meda, personal fees and non-financial support from Novartis, non-financial support from Otonomy, personal fees from Stada, and UCB, non-financial support from Ferrero, grants from BitopAG, Hulka, personal fees from Nuvo, grants from Ursapharm, personal fees from Menarini, Mundipharma, Pohl-Boskamp, grants from Inmunotek. The authors report no other potential conflicts of interest in this work.

Figures

Figure 1
Figure 1
The treatment strategy by pharmacotherapy in allergic rhinitis.
See this image and copyright information in PMC

References

    1. Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The international study of the allergic rhinitis survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8(1):e7. doi:10.5415/apallergy.2018.8.e7 - DOI - PMC - PubMed
    1. Cingi C, Gevaert P, Mösges R, et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology task force report. Clin Transl Allergy. 2017;7(1):17. doi:10.1186/s13601-017-0153-z - DOI - PMC - PubMed
    1. Katelaris CH, Lai CKW, Rhee CS, et al. Nasal allergies in the Asian-Pacific population: results from the allergies in Asia-Pacific survey. Am J Rhinol Allergy. 2011;25(Suppl 1):S3–S15. doi:10.2500/ajra.2011.25.3674 - DOI - PubMed
    1. Ho TM, Murad S, Kesavapillai R, Singaram SP. Prevalence of allergy to some inhalants among rhinitis patients in Malaysia. Asian Pac J Allergy Immunol. 1995;13(1):11–16. - PubMed
    1. Brozek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi:10.1016/j.jaci.2017.03.050 - DOI - PubMed